Michel Ducreux
Department of Medicine
Gustave Roussy Institute
Villejuif
France
Name/email consistency: high
- Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Ducreux, M., Bennouna, J., Hebbar, M., Ychou, M., Lledo, G., Conroy, T., Adenis, A., Faroux, R., Rebischung, C., Bergougnoux, L., Kockler, L., Douillard, J.Y. Int. J. Cancer (2011)
- Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. Oberic, L., Viret, F., Baey, C., Ychou, M., Bennouna, J., Adenis, A., Peiffert, D., Mornex, F., Pignon, J.P., Celier, P., Berille, J., Ducreux, M. Radiat. Oncol (2011)
- High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases? Ducreux, M., Raoul, J.L., Marti, P., Merrouche, Y., Tigaud, J.M., Rebischung, C., Boige, V. Oncology (2008)
- Treatment of advanced pancreatic cancer. Ducreux, M., Boige, V., Malka, D. Semin. Oncol. (2007)
- The multidisciplinary management of gastrointestinal cancer. Pancreatic cancer: from pathogenesis to cure. Ducreux, M., Boige, V., Goéré, D., Deutsch, E., Ezra, P., Elias, D., Malka, D. Best. Pract. Res. Clin. Gastroenterol (2007)
- Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. Ducreux, M., Bouche, O., Pignon, J.P., Mousseau, M., Raoul, J.L., Cassan, P., Leduc, B., Berger, C., Dunant, A., Fournet, J., Bedenne, L. Oncology (2006)
- A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Ducreux, M., Van Cutsem, E., Van Laethem, J.L., Gress, T.M., Jeziorski, K., Rougier, P., Wagener, T., Anak, O., Baron, B., Nordlinger, B. Eur. J. Cancer (2005)
- Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Ducreux, M., Ychou, M., Laplanche, A., Gamelin, E., Lasser, P., Husseini, F., Quenet, F., Viret, F., Jacob, J.H., Boige, V., Elias, D., Delperro, J.R., Luboinski, M. J. Clin. Oncol. (2005)
- Emerging drugs in pancreatic cancer. Ducreux, M., Boige, V., Malka, D. Expert. Opin. Emerg. Drugs (2004)
- A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ducreux, M., Rougier, P., Pignon, J.P., Douillard, J.Y., Seitz, J.F., Bugat, R., Bosset, J.F., Merouche, Y., Raoul, J.L., Ychou, M., Adenis, A., Berthault-Cvitkovic, F., Luboinski, M. Ann. Oncol. (2002)